He holds a degree in Biochemistry (University of Barcelona) and a Master’s in Business Management applied to the Biotechnology and Pharmaceutical Industry (BBI). He has built his career in biotechnology venture capital, with experience in investment and value creation across the European life sciences ecosystem.
He joined Invivo Partners in February 2026.
Previously, he worked as an Associate at INKEF Capital (Amsterdam) and as an Analyst at Inveready (Barcelona), contributing to due diligence, investments, and portfolio management of biotech companies, acting as a board observer at Draupnir Bio, VarmX, Scenic Biotech, TargED Biopharmaceuticals, iOnctura, and Anavo Therapeutics.
Throughout his career, he has supported the development of scientific and strategic theses, the advancement of translational pipelines, and the preparation of financing rounds and strategic partnerships, with a focus on building biopharmaceutical companies with the potential to deliver meaningful impact for patients.
